Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: Experience from a national registry (GRAID)

Arthritis Research and Therapy

Volumn 13, Issue 3, 2011, Pages

  Tony, Hans Peter ^a   Burmester, Gerd ^b   Schulze Koops, Hendrik ^c   Grunke, Mathias ^c   Henes, Joerg ^d   Kötter, Ina ^d   Haas, Judith ^e   Unger, Leonore ^f   Lovric, Svjetlana ^g   Haubitz, Marion ^g   Fischer Betz, Rebecca ^h   Chehab, Gamal ^h   Rubbert Roth, Andrea ⁱ   Specker, Christof ^j   Weinerth, Jutta ^k   Holle, Julia ^l   Müller Ladner, Ulf ^m   König, Ramona ^m   Fiehn, Christoph ⁿ   Burgwinkel, Philip ^b   Budde, Klemens ^b   Sörensen, Helmut ^o   Meurer, Michael ^p   Aringer, Martin ^p   Kieseier, Bernd ^h   Erfurt Berge, Cornelia ^q   Sticherling, Michael ^q   Veelken, Roland ^q   Ziemann, Ulf ^r   Strutz, Frank ^s   von Wussow, Praxis ^t   Meier, Florian M P ^u   Hunzelmann, Nico ^v   Schmidt, Enno ^w,aj   Bergner, Raoul ^x   Schwarting, Andreas ^y   Eming, Rüdiger ^z   Hertl, Michael ^z   Stadler, Rudolf ^aa   Schwarz Eywill, Michael ^ab   Wassenberg, Siegfried ^ac   Fleck, Martin ^ad   Metzler, Claudia ^ae   Zettl, Uwe ^af   Westphal, Jens ^ag   Heitmann, Stefan ^ah   Herzog, Anna L ^ai   Wiendl, Heinz ^ai   Jakob, Waltraud ^aj   Freivogel, Klaus ^aj   Dörner, Thomas ^b   more..

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e Judisches Krankenhaus Berlin   (Germany)

^f ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^j Eye Hospital   (Germany)

^k KLINIKUM AUGSBURG   (Germany)

^l UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^m KERCKHOFF HEART CENTER   (Germany)

ⁿ ACURA Rheumazentrum Baden Baden   (Germany)

^o Ambulantes Rheumazentrum   (Germany)

^p DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^q UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^r UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^s UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^t Gesell fur Padiatrische Onkologie   (Germany)

^u Rheumapraxis Hofheim   (Germany)

^v UNIVERSITY OF COLOGNE   (Germany)

^w Institut für Humangenetik   (Germany)

^x KLINIKUM LUDWIGSHAFEN   (Germany)

^y UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^z PHILIPPS UNIVERSITY MARBURG   (Germany)

^aa KLINIKUM MINDEN   (Germany)

^ab EVANGELISCHES KRANKENHAUS   (Germany)

^ac Ev Fachkrankenhaus Ratingen ^*  (Germany)

^ad UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^ae Krankenhaus der Barmherzigen Bruder   (Germany)

^af ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^ag Praxis für Allgemeinmedizin   (Germany)

^ah MARIENHOSPITAL STUTTGART   (Germany)

^ai UNIVERSITY OF WÜRZBURG   (Germany)

^aj Analytica International   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; CANDIDIASIS; CONTROLLED STUDY; CRYOGLOBULINEMIA; DERMATOLOGY; DERMATOMYOSITIS; DISEASE REGISTRY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL INFECTION; GLOMERULONEPHRITIS; HEALTH CARE QUALITY; HERPES ZOSTER; HUMAN; INFECTION RATE; LISTERIOSIS; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MIXED CONNECTIVE TISSUE DISEASE; MORTALITY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYCOSIS; NEPHROLOGY; NEUROLOGY; OPPORTUNISTIC INFECTION; PEMPHIGUS; PLASMAPHERESIS; PSORIATIC ARTHRITIS; RHEUMATOLOGY; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; VASCULITIS; WEGENER GRANULOMATOSIS; CLINICAL TRIAL; DRUG RESISTANCE; GERMANY; HEALTH STATUS; IMMUNOLOGY; MULTICENTER STUDY; PATIENT SATISFACTION; REGISTER; RETROSPECTIVE STUDY; STATISTICS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; DRUG HYPERSENSITIVITY; DRUG RESISTANCE; FOLLOW-UP STUDIES; GERMANY; HEALTH STATUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATIENT SATISFACTION; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79955825182     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3337     Document Type: Article

References (72)

1. Dörner T, Burmester GR. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol 2003, 15:246-252. 10.1097/00002281-200305000-00011, 12707577.
2. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006, 6:394-403. 10.1038/nri1838, 16622478.
3. Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010, 6:326-337. 10.1038/nrrheum.2010.68, 20520647.
4. Dörner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 2009, 5:433-441. 10.1038/nrrheum.2009.141, 19581902.
5. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003, 48:1484-1492. 10.1002/art.10947, 12794814.
6. Lee S, Ballow M. Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases. J Allergy Clin Immunol 2010, 125:814-820. 10.1016/j.jaci.2010.02.025, 20371395.
7. Dörner T, Isenberg D, Jayne D, Wiendl H, Zillikens D, Burmester G. International Roundtable on B cells as Therapeutic Target for Intervention: Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev 2009, 9:82. 10.1016/j.autrev.2009.08.007, 19716441.
8. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR, . European Vasculitis Study Group Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363:211-220. 10.1056/NEJMoa0909169, 20647198, European Vasculitis Study Group.
9. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, . RAVE-ITN Research Group Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232. 10.1056/NEJMoa0909905, 20647199, RAVE-ITN Research Group.
10. Falk RJ, Jennette JC. Rituximab in ANCA-associated disease. N Engl J Med 2010, 363:285-286. 10.1056/NEJMe1004992, 20647204.
11. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, . REFLEX Trial Group Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806. 10.1002/art.22025, 16947627, REFLEX Trial Group.
12. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581. 10.1056/NEJMoa032534, 15201414.
13. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM, . DANCER Study Group The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006, 54:1390-1400. 10.1002/art.21778, 16649186, DANCER Study Group.
14. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, Latinis K, Abud-Mendoza C, Szczepanski LJ, Roschmann RA, Chen A, Armstrong GK, Douglass W, Tyrrell H. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biologic-naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010, 69:1629-1635. 10.1136/ard.2009.119933, 2938895, 20488885.
15. Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M, Agarwal S, Yin M, Kelman A. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol 2010, 37:917-927. 10.3899/jrheum.090442, 20194448.
16. Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreño L, Armstrong G, Collinson N, Shaw TM, . MIRROR Trial Investigators Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 2010, 49:1683-1693. MIRROR Trial Investigators.
17. van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, Rao R. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheum 2010, 37:558-567. 10.3899/jrheum.090856, 20110520.
18. Avshovich N, Boulman N, Slobodin G, Zeina AR, Rosner I, Rozenbaum M. Refractory Wegener's granulomatosis: effect of rituximab on granulomatous bilateral orbital involvement. Isr Med Assoc J 2009, 11:566-568.
19. Huerva V, Sanchez MC, Traveset A, Jurjo C, Ruiz A. Rituximab for peripheral ulcerative keratitis with Wegener granulomatosis. Cornea 2010, 29:708-710.
20. Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, Savage CO, Jayne DR. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009, 60:2156-2168. 10.1002/art.24637, 19565480.
21. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52:262-268. 10.1002/art.20718, 15641078.
22. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006, 173:180-187. 2662987, 16224107.
23. Martinez Del Pero M, Chaudhry A, Jones RB, Sivasothy P, Jani P, Jayne D. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol 2009, 34:328-335. 10.1111/j.1749-4486.2009.01968.x, 19673980.
24. Patel AM, Lehman TJ. Rituximab for severe refractory pediatric Wegener granulomatosis. J Clin Rheumatol 2008, 14:278-280. 10.1097/RHU.0b013e3181886064, 18824926.
25. Seo P, Specks U, Keogh KA. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008, 35:2017-2023.
26. Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001, 44:2836-2840. 10.1002/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W, 11762944.
27. Staines KS, Higgins B. Recurrence of Wegener's granulomatosis with de novo intraoral presentation treated successfully with rituximab. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009, 108:76-80. 10.1016/j.tripleo.2009.02.025, 19451001.
28. Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009, 60:1540-1547. 10.1002/art.24454, 19404964.
29. Lovric S, Erdbruegger U, Kümpers P, Woywodt A, Koenecke C, Wedemeyer H, Haller H, Haubitz M. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody associated vasculitis: single centre experience with fifteen patients. Nephrol Dial Transplant 2009, 24:179-185.
30. Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, Gougeon ML, Bedane C, Muller R, Dreno B, Doutre MS, Delaporte E, Pauwels C, Franck N, Caux F, Picard C, Tancrede-Bohin E, Bernard P, Tron F, Hertl M, Musette P. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007, 357:545-552. 10.1056/NEJMoa067752, 17687130.
31. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006, 355:1772-1779. 10.1056/NEJMoa062930, 17065638.
32. Nagel A, Podstawa E, Eickmann M, Müller HH, Hertl M, Eming R. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol 2009, 129:2202-2210. 10.1038/jid.2009.27, 19282839.
33. Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci 2009, 1173:683-691. 10.1111/j.1749-6632.2009.04744.x, 19758216.
34. Quartuccio L, Soardo G, Romano G, Zaja F, Scott CA, De Marchi G, Fabris M, Ferraccioli G, De Vita S. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology 2006, 45:842-846. 10.1093/rheumatology/kel004, 16418196.
35. Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, Michelutti A, Baccarani M, Fanin R, Ferraccioli G. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003, 101:3827-3834. 10.1182/blood-2002-09-2856, 12560225.
36. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005, 52:601-607. 10.1002/art.20849, 15692974.
37. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003, 48:455-459. 10.1002/art.10764, 12571855.
38. Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, Sanz I. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007, 56:3044-3056. 10.1002/art.22810, 17763423.
39. Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, Stohl W. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008, 67:1011-1016.
40. Catapano F, Chaudhry AN, Jones RB, Smith KG, Jayne DW. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant 2010, 25:3586-3592. 10.1093/ndt/gfq256, 20466686.
41. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002, 46:2673-2677. 10.1002/art.10541, 12384926.
42. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005, 44:1542-1545.
43. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004, 50:2580-2589. 10.1002/art.20430, 15334472.
44. Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009, 61:482-487. 10.1002/art.24341, 19333973.
45. Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007, 66:1259-1262. 10.1136/ard.2006.067124, 1955162, 17412738.
46. Aries PM, Hellmich B, Voswinkel J, Both M, Nölle B, Holl-Ulrich K, Lamprecht P, Gross WL. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006, 65:853-858. 1798224, 16269425.
47. Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 2007, 25:S23-S27.
48. Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 2005, 34:229-232. 10.1080/02813430510015269, 16134730.
49. Tamura N, Matsudaira R, Hirashima M, Ikeda M, Tajima M, Nawata M, Morimoto S, Kaneda K, Kobayashi S, Hashimoto H, Takasaki Y. Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med 2007, 46:409-414. 10.2169/internalmedicine.46.6156, 17409608.
50. Cohen H, Green S, Jones S, Amos N, William BD. Lack of efficacy of rituximab in a patient with essential mixed cryoglobulinaemia. Rheumatology (Oxford) 2007, 46:366-367.
51. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007, 143:763-767. 10.1001/archderm.143.6.763, 17576943.
52. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, Sieper J. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010, 62:1290-1297. 10.1002/art.27383, 20461780.
53. Wendling D, Augé B, Streit G, Toussirot E, Mathieu S. Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis. Joint Bone Spine 2008, 75:510-511. 10.1016/j.jbspin.2008.01.023, 18457981.
54. Sène D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P. Rituximab may form a complex with IgM kappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009, 60:3848-3855. 10.1002/art.25000, 19950292.
55. Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005, 62:258-264. 10.1001/archneur.62.2.258, 15710854.
56. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH, . HERMES Trial Group B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688. 10.1056/NEJMoa0706383, 18272891, HERMES Trial Group.
57. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH, . OLYMPUS trial group Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009, 66:460-471. 10.1002/ana.21867, 19847908, OLYMPUS trial group.
58. Furie R, Looney RJ, Rovin B, Latinis KM, Appel G, Sanchez-Guerrero J, Fervenza FC, Maciuca R, Brunetta P, Zhang D, Garg J. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum 2009, 60(Suppl 10):1149.
59. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222-233. 10.1002/art.27233, 20039413.
60. Ramos-Casals M, Garcia-Hernandez FJ, De Ramon E, Callejas JL, Martinez-Berriotxoa A, Pallares L, Caminal-Montero L, Selva-O'Callaghan A, Oristrell J, Hidalgo C, Perez-Alvarez R, Mico ML, Medrano F, Gomez de la Torre R, Diaz-Lagares C, Camps MT, Ortego N, Sanchez-Roman J. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010, 28:468-476.
61. Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harlé JR, Hot A, Kahn JE, Lambotte O, Larroche C, Léone J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010, 62:2458-2466. 10.1002/art.27541, 20506527.
62. Lipsky PE, Dörner T. The red wolf remains a wily foe. Nat Rev Rheumatol 2010, 6:307-308. 10.1038/nrrheum.2010.83, 20520644.
63. Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, Dougados M, Flipo RM, Godeau B, Guillevin L, Le Loët X, Hachulla E, Schaeverbeke T, Sibilia J, Baron G, Mariette X, . AutoImmunity and Rituximab Registry and French Society of Rheumatology Risk factors of severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010, 62:2625-2632. 10.1002/art.27555, 20506353, AutoImmunity and Rituximab Registry and French Society of Rheumatology.
64. Glück T, Kiefmann B, Grohmann M, Falk W, Straub RH, Schölmerich J. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol 2005, 32:1473-1480.
65. Emery P, Mease PJ, Rubbert-Roth A, Curtis JR, Müller-Ladner U, Gaylis N, Williams S, Tyrell H, Reynard M. Retreatment with rituximab based on a treatment to target approach provides better disease control than treatment as needed in patients with RA [abstract]. Ann Rheum Dis 2010, 69(Suppl 3):382.
66. Teng YK, Tekstra J, Breedveld FC, Lafeber F, Bijlsma JW, van Laar JM. Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies. Ann Rheum Dis 2009, 68:1075-1077. 10.1136/ard.2008.100438, 19435725.
67. Airio A, Kautiainen H, Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006, 25:234-239. 10.1007/s10067-005-1164-z, 16477398.
68. Charlier C, Henegar C, Launay O, Pagnoux C, Berezné A, Bienvenu B, Cohen P, Mouthon L, Guillevin L. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis 2009, 68:658-663. 10.1136/ard.2008.088302, 18504289.
69. Fardet L, Rybojad M, Gain M, Kettaneh A, Cherin P, Bachelez H, Dubertret L, Lebbe C, Morel P, Dupuy A. Incidence, risk factors, and severity of herpes virus infections in a cohort of 121 patients with primary dermatomyositis and dermatomyositis associated with a malignant neoplasm. Arch Dermatol 2009, 145:889-893. 10.1001/archdermatol.2009.152, 19687419.
70. Phillip R, Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol 2008, 26:S94-S104.
71. Sunesen KG, Nørgaard M, Thorlacius-Ussing O, Laurberg S. Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005. Int J Cancer 2010, 127:675-684. 10.1002/ijc.25080, 19960431.
72. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006, 54:2970-2982. 10.1002/art.22046, 16947528.